These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6402859)

  • 1. The antithrombin III content of cryoprecipitate prepared from blood collected with and without heparin.
    Cosgriff TM; Hodgson LA; West JV
    Vox Sang; 1983; 44(2):98-101. PubMed ID: 6402859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of disseminated intravascular coagulation].
    Matsuda T
    Rinsho Byori; 1985 Jun; Spec No 63():79-89. PubMed ID: 3930817
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats.
    Hauptmann J; Brüggener E; Markwardt F
    Haemostasis; 1987; 17(6):321-8. PubMed ID: 3428717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
    Sandler RM; Liebman HA; Patch MJ; Teitelbaum A; Levine AM; Feinstein DI
    Cancer; 1983 Feb; 51(4):681-5. PubMed ID: 6571800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin III patterns in disseminated intravascular coagulation.
    Bick RL; Bick MD; Fekete LF
    Am J Clin Pathol; 1980 Apr; 73(4):577-83. PubMed ID: 7369182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of heparin and/or antithrombin III in a model of disseminated intravascular coagulation induced by endotoxin in rabbits].
    Gómez C; Páramo JA; Rocha E
    Sangre (Barc); 1992 Feb; 37(1):5-10. PubMed ID: 1585238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
    Sandler RM; Liebman HA; Patch MJ; Teitelbaum A; Levine AM; Feinstein DI
    Cancer; 1982 Nov; 50(10):2106-10. PubMed ID: 6957257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of disseminated intravascular coagulation with antithrombin III concentrate in children with verified infection].
    Nowak-Göttl U; Groll A; Kreuz WD; Brand M; Breddin HK; von Loewenich V; Kornhuber B
    Klin Padiatr; 1992; 204(3):134-40. PubMed ID: 1614177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombin III in fresh frozen plasma, cryoprecipitate, and cryoprecipitate-depleted plasma.
    Mintz PD; Blatt PM; Kuhns WJ; Roberts HR
    Transfusion; 1979; 19(5):597-8. PubMed ID: 505534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitution therapy with an antithrombin III concentrate in shock and DIC.
    Blauhut B; Necek S; Vinazzer H; Bergmann H
    Thromb Res; 1982 Aug; 27(3):271-8. PubMed ID: 7135359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disseminated intravascular coagulation with multiple arterial thromboses responding to antithrombin-III concentrate infusion.
    Wisecarver JL; Haire WD
    Thromb Res; 1989 Jun; 54(6):709-17. PubMed ID: 2781511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of antithrombin III concentrates in disseminated intravascular coagulation].
    Aoki N; Matsuki K; Sakata Y
    Rinsho Ketsueki; 1982 Jun; 23(6):804-10. PubMed ID: 7176087
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antithrombin III substitution in patients in shock].
    Vinazzer H; Blauhut B; Bergmann H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):806-16. PubMed ID: 6083957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin III concentrates for treatment of disseminated intravascular coagulation in children.
    Hanada T; Abe T; Takita H
    Am J Pediatr Hematol Oncol; 1985; 7(1):3-8. PubMed ID: 4037242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo attempt to consume antithrombin III by i.v. injection of a thrombin-heparin mixture.
    Soulier JP; Gozin D; Lerable J
    Thromb Res; 1984 May; 34(3):255-62. PubMed ID: 6729779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombin III: critical review of assay methods. Significance of variations in health and disease.
    Odegård OR; Abildgaard U
    Haemostasis; 1978; 7(2-3):127-34. PubMed ID: 350729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of antithrombin III concentrates].
    Vinazzer H
    Beitr Infusionsther; 1989; 24():151-8. PubMed ID: 2481532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current views on the therapeutic use of heparin and antithrombin III in disseminated intravascular coagulation].
    Sobczyk J; Swietliński J; Podleśny-Owsińska T
    Pol Tyg Lek; 1989 Oct 2-16; 44(40-42):896-8. PubMed ID: 2487947
    [No Abstract]   [Full Text] [Related]  

  • 19. Heparin cofactor activity measured with an amidolytic method.
    Odegard OR; Lie M; Abildgaard U
    Thromb Res; 1975 Apr; 6(4):287-94. PubMed ID: 49087
    [No Abstract]   [Full Text] [Related]  

  • 20. Revisiting antithrombin in health and disease, congenital deficiencies and genetic variants, and laboratory studies on α and β forms.
    Amiral J; Seghatchian J
    Transfus Apher Sci; 2018 Apr; 57(2):291-297. PubMed ID: 29784539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.